vs
Side-by-side financial comparison of Satellogic Inc. (SATL) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Satellogic Inc. is the larger business by last-quarter revenue ($6.2M vs $5.5M, roughly 1.1× Taysha Gene Therapies, Inc.). Satellogic Inc. runs the higher net margin — 488.0% vs -507.8%, a 995.7% gap on every dollar of revenue.
Satellogic Inc. is an American company specializing in Earth-observation satellites, founded in 2010 by Emiliano Kargieman and Gerardo Richarte.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
SATL vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.2M | $5.5M |
| Net Profit | $30.5M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -114.2% | -516.0% |
| Net Margin | 488.0% | -507.8% |
| Revenue YoY | — | 171.3% |
| Net Profit YoY | — | -48.3% |
| EPS (diluted) | $0.24 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.2M | $5.5M | ||
| Q3 25 | $3.6M | $0 | ||
| Q2 25 | $4.4M | $2.0M | ||
| Q1 25 | $3.4M | $2.3M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | $3.5M | $1.1M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | $30.5M | $-27.9M | ||
| Q3 25 | $4.0M | $-32.7M | ||
| Q2 25 | $-6.7M | $-26.9M | ||
| Q1 25 | $-32.6M | $-21.5M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | $-18.1M | $-20.9M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | -114.2% | -516.0% | ||
| Q3 25 | -222.5% | — | ||
| Q2 25 | -141.6% | -1347.1% | ||
| Q1 25 | -280.9% | -930.5% | ||
| Q4 24 | — | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | -419.2% | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | 488.0% | -507.8% | ||
| Q3 25 | 109.2% | — | ||
| Q2 25 | -149.8% | -1353.6% | ||
| Q1 25 | -961.9% | -935.2% | ||
| Q4 24 | — | -929.0% | ||
| Q3 24 | — | -1427.5% | ||
| Q2 24 | -517.0% | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | $0.24 | $-0.08 | ||
| Q3 25 | $-0.02 | $-0.09 | ||
| Q2 25 | $-0.06 | $-0.09 | ||
| Q1 25 | $-0.34 | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | $-0.20 | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $94.4M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $60.5M | $246.9M |
| Total Assets | $151.3M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.4M | $319.8M | ||
| Q3 25 | $28.3M | $297.3M | ||
| Q2 25 | $32.6M | $312.8M | ||
| Q1 25 | $17.7M | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | $25.6M | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $60.5M | $246.9M | ||
| Q3 25 | $-56.9M | $219.0M | ||
| Q2 25 | $-68.1M | $248.7M | ||
| Q1 25 | $-83.1M | $55.1M | ||
| Q4 24 | — | $71.5M | ||
| Q3 24 | — | $88.8M | ||
| Q2 24 | $19.1M | $108.9M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | $151.3M | $343.3M | ||
| Q3 25 | $70.9M | $316.6M | ||
| Q2 25 | $73.8M | $333.3M | ||
| Q1 25 | $61.4M | $138.4M | ||
| Q4 24 | — | $160.4M | ||
| Q3 24 | — | $180.2M | ||
| Q2 24 | $76.6M | $200.4M | ||
| Q1 24 | — | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.5M | $-26.7M |
| Free Cash FlowOCF − Capex | $-12.8M | — |
| FCF MarginFCF / Revenue | -204.9% | — |
| Capex IntensityCapex / Revenue | 53.6% | — |
| Cash ConversionOCF / Net Profit | -0.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-34.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.5M | $-26.7M | ||
| Q3 25 | $-8.4M | $-24.2M | ||
| Q2 25 | $-4.3M | $-20.2M | ||
| Q1 25 | $-4.7M | $-22.0M | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.5M | ||
| Q1 24 | — | $-19.8M |
| Q4 25 | $-12.8M | — | ||
| Q3 25 | $-9.7M | $-24.3M | ||
| Q2 25 | $-5.1M | — | ||
| Q1 25 | $-6.6M | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | -204.9% | — | ||
| Q3 25 | -267.2% | — | ||
| Q2 25 | -115.3% | — | ||
| Q1 25 | -195.9% | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 53.6% | — | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 56.5% | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | -0.31× | — | ||
| Q3 25 | -2.11× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SATL
| Transferred At Point In Time | $5.7M | 91% |
| Other | $547.0K | 9% |
TSHA
Segment breakdown not available.
